Cargando…

A 10-year retrospective study of lung cancer in Uganda

BACKGROUND: Lung cancer is a leading cause of cancer-related deaths in Uganda. In this study, we aimed to describe the baseline characteristics and survival of patients with lung cancer at the Uganda Cancer Institute (UCI). METHODS: We retrospectively reviewed medical records of all patients with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bogere, Naghib, Bongomin, Felix, Katende, Andrew, Omaido, Blair Andrew, Namukwaya, Elizabeth, Mayanja-Kizza, Harriet, Walusansa, Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867773/
https://www.ncbi.nlm.nih.gov/pubmed/35197014
http://dx.doi.org/10.1186/s12885-022-09300-1
_version_ 1784656121962692608
author Bogere, Naghib
Bongomin, Felix
Katende, Andrew
Omaido, Blair Andrew
Namukwaya, Elizabeth
Mayanja-Kizza, Harriet
Walusansa, Victoria
author_facet Bogere, Naghib
Bongomin, Felix
Katende, Andrew
Omaido, Blair Andrew
Namukwaya, Elizabeth
Mayanja-Kizza, Harriet
Walusansa, Victoria
author_sort Bogere, Naghib
collection PubMed
description BACKGROUND: Lung cancer is a leading cause of cancer-related deaths in Uganda. In this study, we aimed to describe the baseline characteristics and survival of patients with lung cancer at the Uganda Cancer Institute (UCI). METHODS: We retrospectively reviewed medical records of all patients with a histological diagnosis of lung cancer registered at UCI between January 2008 and August 2018. Data on demographic, clinical, and treatment characteristics, and vital status were abstracted and analyzed. Patients with undocumented vital status on the medical records were contacted through phone calls. We determined survival as time from histological diagnosis to death. The Kaplan-Meier survival analysis was performed to estimate the median survival time and the 5-year overall survival rate. RESULTS: Of the 207 patients enrolled, 56.5% (n = 117) were female, median age was 60 years (range: 20–94), 78.7% (n = 163) were never-smokers and 18 (8.7%) were living with HIV. Presumptive anti-tuberculosis treatment was given to 23.2% (n = 48). Majority had non-small cell lung cancer (96.6%, n = 200) with 74.5% (n = 149) adenocarcinoma and 19% (n = 38) squamous cell carcinoma. All had advanced (stage III or IV) disease with 96.1% (n = 199) in stage IV. Chemotherapy (44.9%, n = 93) and biological therapy (34.8%, n = 72) were the commonest treatments used. Overall survival at 6 months, 1-, 2- and 5-years was 41.7, 29.7, 11.8, and 1.7%, respectively. The median survival time of 4.4 months was not statistically significantly different between participants with NSCLC or SCLC (4.5 versus 3.9 months, p = .335). CONCLUSION: In Uganda, adenocarcinoma is the predominant histologic subtype of lung cancer and patients are predominantly females, and non-smokers. Patients present late with advanced disease and poor overall survival. Public awareness should be heightened to facilitate early detection and improve outcomes.
format Online
Article
Text
id pubmed-8867773
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88677732022-02-25 A 10-year retrospective study of lung cancer in Uganda Bogere, Naghib Bongomin, Felix Katende, Andrew Omaido, Blair Andrew Namukwaya, Elizabeth Mayanja-Kizza, Harriet Walusansa, Victoria BMC Cancer Research BACKGROUND: Lung cancer is a leading cause of cancer-related deaths in Uganda. In this study, we aimed to describe the baseline characteristics and survival of patients with lung cancer at the Uganda Cancer Institute (UCI). METHODS: We retrospectively reviewed medical records of all patients with a histological diagnosis of lung cancer registered at UCI between January 2008 and August 2018. Data on demographic, clinical, and treatment characteristics, and vital status were abstracted and analyzed. Patients with undocumented vital status on the medical records were contacted through phone calls. We determined survival as time from histological diagnosis to death. The Kaplan-Meier survival analysis was performed to estimate the median survival time and the 5-year overall survival rate. RESULTS: Of the 207 patients enrolled, 56.5% (n = 117) were female, median age was 60 years (range: 20–94), 78.7% (n = 163) were never-smokers and 18 (8.7%) were living with HIV. Presumptive anti-tuberculosis treatment was given to 23.2% (n = 48). Majority had non-small cell lung cancer (96.6%, n = 200) with 74.5% (n = 149) adenocarcinoma and 19% (n = 38) squamous cell carcinoma. All had advanced (stage III or IV) disease with 96.1% (n = 199) in stage IV. Chemotherapy (44.9%, n = 93) and biological therapy (34.8%, n = 72) were the commonest treatments used. Overall survival at 6 months, 1-, 2- and 5-years was 41.7, 29.7, 11.8, and 1.7%, respectively. The median survival time of 4.4 months was not statistically significantly different between participants with NSCLC or SCLC (4.5 versus 3.9 months, p = .335). CONCLUSION: In Uganda, adenocarcinoma is the predominant histologic subtype of lung cancer and patients are predominantly females, and non-smokers. Patients present late with advanced disease and poor overall survival. Public awareness should be heightened to facilitate early detection and improve outcomes. BioMed Central 2022-02-23 /pmc/articles/PMC8867773/ /pubmed/35197014 http://dx.doi.org/10.1186/s12885-022-09300-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bogere, Naghib
Bongomin, Felix
Katende, Andrew
Omaido, Blair Andrew
Namukwaya, Elizabeth
Mayanja-Kizza, Harriet
Walusansa, Victoria
A 10-year retrospective study of lung cancer in Uganda
title A 10-year retrospective study of lung cancer in Uganda
title_full A 10-year retrospective study of lung cancer in Uganda
title_fullStr A 10-year retrospective study of lung cancer in Uganda
title_full_unstemmed A 10-year retrospective study of lung cancer in Uganda
title_short A 10-year retrospective study of lung cancer in Uganda
title_sort 10-year retrospective study of lung cancer in uganda
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867773/
https://www.ncbi.nlm.nih.gov/pubmed/35197014
http://dx.doi.org/10.1186/s12885-022-09300-1
work_keys_str_mv AT bogerenaghib a10yearretrospectivestudyoflungcancerinuganda
AT bongominfelix a10yearretrospectivestudyoflungcancerinuganda
AT katendeandrew a10yearretrospectivestudyoflungcancerinuganda
AT omaidoblairandrew a10yearretrospectivestudyoflungcancerinuganda
AT namukwayaelizabeth a10yearretrospectivestudyoflungcancerinuganda
AT mayanjakizzaharriet a10yearretrospectivestudyoflungcancerinuganda
AT walusansavictoria a10yearretrospectivestudyoflungcancerinuganda
AT bogerenaghib 10yearretrospectivestudyoflungcancerinuganda
AT bongominfelix 10yearretrospectivestudyoflungcancerinuganda
AT katendeandrew 10yearretrospectivestudyoflungcancerinuganda
AT omaidoblairandrew 10yearretrospectivestudyoflungcancerinuganda
AT namukwayaelizabeth 10yearretrospectivestudyoflungcancerinuganda
AT mayanjakizzaharriet 10yearretrospectivestudyoflungcancerinuganda
AT walusansavictoria 10yearretrospectivestudyoflungcancerinuganda